SequelSEC

Dianthus Therapeutics, Inc. /DE/ DNTH

Pharmaceutical Preparations · CIK 0001690585 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$2.04M
Fiscal year ended 2025-12-31
Operating income
-$177.93M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$599.40MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$13.48Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue294.4×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue7153.1%91th
SBC / revenue1119.5%89th
Operating margin-8739.3%12th
Net margin-7973.3%12th
Current ratio13.32x87th
Revenue YoY growth-67.3%19th

Dianthus Therapeutics, Inc. /DE/ (DNTH) reported revenue of $2.04M and net income of -$162.34M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Dianthus Therapeutics, Inc. /DE/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Dianthus Therapeutics, Inc. /DE/ income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Revenue$2.04M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$177.93M
Net income-$162.34M
Research & development$145.64M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$34.33M
Selling & marketingUnavailable

Balance

Dianthus Therapeutics, Inc. /DE/ balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Cash & equivalents$51.09M
Total assets$530.92M
Current assets$409.44M
Total liabilities$37.52M
Current liabilities$30.73M
Total equity incl. NCI$493.40M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$52.00K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$9.72M

Cash flow

Dianthus Therapeutics, Inc. /DE/ cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Operating cash flow-$129.06M
Capital expendituresUnavailable
Investing cash flow-$122.83M
Financing cash flow$280.12M
Net change in cash$28.23M
Stock-based compensation$22.79M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Dianthus Therapeutics, Inc. /DE/ derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-8739.3%
FCF marginUnavailable
SBC / revenue1119.5%
Current ratio13.32x
Revenue YoY growth-67.3%
Net margin-7973.3%
R&D / revenue7153.1%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DNTH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.